FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313371716> ?p ?o ?g. }

• W4313371716 endingPage "19???30" @default.
• W4313371716 startingPage "19???30" @default.
• W4313371716 abstract "Objective To describe several emerging concepts regarding the biosynthesis, metabolism and biological roles of adenosine and to illustrate the possible significance of these ideas to vascular biology by proposing a hypothesis pertaining to the role of erythrocyte-derived adenosine deaminase in vaso-occlusive diseases associated with damaged erythrocytes. Multiple pathways for adenosine formation Three pathways of adenosine biosynthesis have been well established: the intracellular ATP pathway, the extracellular ATP pathway and the transmethylation pathway. A fourth pathway that has received relatively little attention, but could be particularly important in vascular smooth muscle, is the cyclic AMP-adenosine pathway. This pathway involves the extracellular or intracellular metabolism, or both, of cyclic AMP to AMP and hence to adenosine. Our recent experiments in cultured vascular smooth muscle cells, isolated vascular beds and intact animals support the existence of the cyclic AMP-adenosine pathway. Together these four pathways of adenosine formation should assure pharmacologically active levels of vascular adenosine. Antivaso-occlusive actions of adenosine The overall pharmacologic profile of adenosine suggests that this nucleoside functions to protect vascular beds from vaso-occlusive events. In this regard, some well known effects of adenosine include vasodilation, release of nitric oxide from vascular endothelial cells and inhibition of platelet aggregation, platelet adhesion, neutrophil-endothelial interactions, renin release and noradrenergic neurotransmission. Moreover, studies indicate that adenosine also releases nitric oxide from cultured vascular smooth muscle cells and inhibits vascular smooth muscle cell growth. Thus, any condition that reduces the levels of adenosine in the blood vessel wall or blood vessel-blood interface might predispose toward vaso-occlusive events. Damage to erythrocytes reduces adenosine levels Adenosine deaminase rapidly metabolizes adenosine to inosine, which lacks antivaso-occlusive properties. Because erythrocytes are generously endowed with adenosine deaminase, any condition that damages erythrocytes will cause leakage of adenosine deaminase from erythrocytes directly onto the blood vessel wall, thus diminishing local vascular levels of adenosine. Experiments using dimethyl sulfoxide-induced hemolysis have confirmed the hypothesis that erythrocyte-derived adenosine deaminase can reduce adenosine levels in vivo. Hypothesis: the role of erythrocyte-derived adenosine deaminase in vaso-occlusive diseases Because multiple biosynthetic pathways maintain pharmacologically active levels of adenosine within the blood vessel wall and adenosine exerts a number of antivaso-occlusive effects, release of adenosine deaminase from erythrocytes may increase the risk for vaso-occlusive events." @default.
• W4313371716 created "2023-01-06" @default.
• W4313371716 creator A5011938389 @default.
• W4313371716 creator A5012028041 @default.
• W4313371716 creator A5026244880 @default.
• W4313371716 creator A5028284377 @default.
• W4313371716 creator A5041176674 @default.
• W4313371716 creator A5048598383 @default.
• W4313371716 creator A5057803620 @default.
• W4313371716 date "1996-01-01" @default.
• W4313371716 modified "2023-10-18" @default.
• W4313371716 title "Possible role of adenosine deaminase in vaso-occlusive diseases" @default.
• W4313371716 doi "https://doi.org/10.1097/00004872-199601000-00003" @default.
• W4313371716 hasPublicationYear "1996" @default.
• W4313371716 type Work @default.
• W4313371716 citedByCount "14" @default.
• W4313371716 countsByYear W43133717162013 @default.
• W4313371716 countsByYear W43133717162014 @default.
• W4313371716 countsByYear W43133717162016 @default.
• W4313371716 countsByYear W43133717162017 @default.
• W4313371716 countsByYear W43133717162018 @default.
• W4313371716 countsByYear W43133717162020 @default.
• W4313371716 countsByYear W43133717162022 @default.
• W4313371716 crossrefType "journal-article" @default.
• W4313371716 hasAuthorship W4313371716A5011938389 @default.
• W4313371716 hasAuthorship W4313371716A5012028041 @default.
• W4313371716 hasAuthorship W4313371716A5026244880 @default.
• W4313371716 hasAuthorship W4313371716A5028284377 @default.
• W4313371716 hasAuthorship W4313371716A5041176674 @default.
• W4313371716 hasAuthorship W4313371716A5048598383 @default.
• W4313371716 hasAuthorship W4313371716A5057803620 @default.
• W4313371716 hasConcept C120770815 @default.
• W4313371716 hasConcept C126322002 @default.
• W4313371716 hasConcept C134018914 @default.
• W4313371716 hasConcept C158424129 @default.
• W4313371716 hasConcept C170493617 @default.
• W4313371716 hasConcept C172590197 @default.
• W4313371716 hasConcept C2776991684 @default.
• W4313371716 hasConcept C2778938600 @default.
• W4313371716 hasConcept C2779395532 @default.
• W4313371716 hasConcept C28406088 @default.
• W4313371716 hasConcept C2909627636 @default.
• W4313371716 hasConcept C2992686903 @default.
• W4313371716 hasConcept C34628245 @default.
• W4313371716 hasConcept C519581460 @default.
• W4313371716 hasConcept C55493867 @default.
• W4313371716 hasConcept C67907053 @default.
• W4313371716 hasConcept C71924100 @default.
• W4313371716 hasConcept C79879829 @default.
• W4313371716 hasConcept C86803240 @default.
• W4313371716 hasConcept C95444343 @default.
• W4313371716 hasConcept C98274493 @default.
• W4313371716 hasConceptScore W4313371716C120770815 @default.
• W4313371716 hasConceptScore W4313371716C126322002 @default.
• W4313371716 hasConceptScore W4313371716C134018914 @default.
• W4313371716 hasConceptScore W4313371716C158424129 @default.
• W4313371716 hasConceptScore W4313371716C170493617 @default.
• W4313371716 hasConceptScore W4313371716C172590197 @default.
• W4313371716 hasConceptScore W4313371716C2776991684 @default.
• W4313371716 hasConceptScore W4313371716C2778938600 @default.
• W4313371716 hasConceptScore W4313371716C2779395532 @default.
• W4313371716 hasConceptScore W4313371716C28406088 @default.
• W4313371716 hasConceptScore W4313371716C2909627636 @default.
• W4313371716 hasConceptScore W4313371716C2992686903 @default.
• W4313371716 hasConceptScore W4313371716C34628245 @default.
• W4313371716 hasConceptScore W4313371716C519581460 @default.
• W4313371716 hasConceptScore W4313371716C55493867 @default.
• W4313371716 hasConceptScore W4313371716C67907053 @default.
• W4313371716 hasConceptScore W4313371716C71924100 @default.
• W4313371716 hasConceptScore W4313371716C79879829 @default.
• W4313371716 hasConceptScore W4313371716C86803240 @default.
• W4313371716 hasConceptScore W4313371716C95444343 @default.
• W4313371716 hasConceptScore W4313371716C98274493 @default.
• W4313371716 hasIssue "1" @default.
• W4313371716 hasLocation W43133717161 @default.
• W4313371716 hasOpenAccess W4313371716 @default.
• W4313371716 hasPrimaryLocation W43133717161 @default.
• W4313371716 hasRelatedWork W1975090395 @default.
• W4313371716 hasRelatedWork W2000067854 @default.
• W4313371716 hasRelatedWork W2019407832 @default.
• W4313371716 hasRelatedWork W2023731942 @default.
• W4313371716 hasRelatedWork W2031858427 @default.
• W4313371716 hasRelatedWork W2056056928 @default.
• W4313371716 hasRelatedWork W2103030499 @default.
• W4313371716 hasRelatedWork W2152966409 @default.
• W4313371716 hasRelatedWork W2157684237 @default.
• W4313371716 hasRelatedWork W2883707413 @default.
• W4313371716 hasVolume "14" @default.
• W4313371716 isParatext "false" @default.
• W4313371716 isRetracted "false" @default.
• W4313371716 workType "article" @default.